<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Toxic Dolls | Lindgreen Raymond | Activity</title>
	<link>http://toxicdolls.com/members/goalgeorge91/activity/</link>
	<atom:link href="http://toxicdolls.com/members/goalgeorge91/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Lindgreen Raymond.</description>
	<lastBuildDate>Mon, 09 Nov 2026 22:28:27 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">4986409d80774a8e186c60fb6866d291</guid>
				<title>Lindgreen Raymond posted an update: PURPOSE To study the efficacy of bevacizumab combined with [&#133;]</title>
				<link>http://toxicdolls.com/activity-2/p/61599/</link>
				<pubDate>Sat, 19 Jul 2025 12:41:56 +0000</pubDate>

									<content:encoded><![CDATA[<p>PURPOSE To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. METHODS A total of 100 ovarian cancer patients treated in our hospital from January 2015 to December 2018 were enrolled and divided into experimental group (n=50) and control group&hellip;<span class="activity-read-more" id="activity-read-more-61599"><a href="http://toxicdolls.com/activity-2/p/61599/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a63a52b61b4d0a155d4bb4fa9ad75bed</guid>
				<title>Lindgreen Raymond posted an update: However, there were no statistically significant differences [&#133;]</title>
				<link>http://toxicdolls.com/activity-2/p/58640/</link>
				<pubDate>Thu, 17 Jul 2025 12:48:30 +0000</pubDate>

									<content:encoded><![CDATA[<p>However, there were no statistically significant differences (p &gt; 0.05) for metallic ions concentrations between Group A and Group B. CONCLUSIONS Based on our results, there are no differences in titanium or other metals concentrations in saliva of patients with healthy or diseased implants.Commercially and traditionally managed bees were compared&hellip;<span class="activity-read-more" id="activity-read-more-58640"><a href="http://toxicdolls.com/activity-2/p/58640/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">baa888f28f12c1190a8f20c7539f47ae</guid>
				<title>Lindgreen Raymond posted an update: Factors associated with elevated ESCC risk in this analysis [&#133;]</title>
				<link>http://toxicdolls.com/activity-2/p/41536/</link>
				<pubDate>Thu, 10 Jul 2025 17:05:36 +0000</pubDate>

									<content:encoded><![CDATA[<p>Factors associated with elevated ESCC risk in this analysis included advanced age, being male and smoking. We further identified that the XRCC1 399 Gln/Gln genotype was associated with a significant reduction in ESCC risk prior to propensity matching (odds ratio=0.48; 95% CI 0.23-1.00; P less then 0.05), although this did not remain true following&hellip;<span class="activity-read-more" id="activity-read-more-41536"><a href="http://toxicdolls.com/activity-2/p/41536/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1d792cf4787654e56456c3b92363c5cf</guid>
				<title>Lindgreen Raymond became a registered member</title>
				<link>http://toxicdolls.com/activity-2/p/41503/</link>
				<pubDate>Thu, 10 Jul 2025 16:46:21 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>